Variant Creutzfeldt-Jakob disease

被引:28
|
作者
Ironside, J. W. [1 ]
机构
[1] Univ Edinburgh, Western Gen Hosp, Natl Creutzfeldt Jakob Dis Surveillance Unit, Div Pathol,Sch Mol & Clin Med, Edinburgh, Midlothian, Scotland
基金
英国医学研究理事会;
关键词
blood; haemophilia; plasma; prion; transfusion; variant CJD; BLOOD-TRANSFUSION; PRION PROTEIN; SPONGIFORM ENCEPHALOPATHY; INFECTIVITY; RISK; TRANSMISSION; CJD; PREVALENCE; COMPONENTS; DIAGNOSIS;
D O I
10.1111/j.1365-2516.2010.02317.x
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Variant Creutzfeldt-Jakob disease (CJD) is an emerging form of human prion disease caused by oral exposure to the bovine spongiform encephalopathy agent. Most cases have occurred in the UK, but smaller numbers of cases have been identified in 10 other countries worldwide. All confirmed cases belong to a single genetic subgroup defined by methionine homozygosity at codon 129 in the prion protein gene. Variant CJD has a widespread distribution of infectivity in the body, involving lymphoid tissues during at least the latter part of the incubation period. This is unlike other forms of human prion disease, and raised concerns that the transmissible agent might also be present in blood. To date, four probable cases of variant CJD infection have been identified following transfusion of packed red blood cells from asymptomatic donors who subsequently died from variant CJD. Recently, one case of likely transmission of variant CJD infection by UK factor VIII (FVIII) concentrates has been reported in an elderly haemophilic patient in the UK, who had been treated with FVIII produced from pooled plasma to which a donor who subsequently died from variant CJD had contributed. The recipient showed no signs or symptoms of variant CJD during life, but evidence of variant CJD infection was detected in his spleen following a postmortem examination. Continued surveillance is required to investigate the prevalence of secondary variant CJD infection in other patients with bleeding disorders who have been treated with UK-sourced pooled plasma products.
引用
收藏
页码:175 / 180
页数:6
相关论文
共 50 条
  • [21] Variant Creutzfeldt-Jakob disease: risk of transmission by blood transfusion and blood therapies
    Ironside, JW
    HAEMOPHILIA, 2006, 12 : 8 - 15
  • [22] Creutzfeldt-Jakob disease and the eye
    Head, Mark W.
    Ironside, James W.
    EXPERT REVIEW OF OPHTHALMOLOGY, 2008, 3 (04) : 481 - 490
  • [23] Creutzfeldt-Jakob disease
    Iwasaki, Yasushi
    NEUROPATHOLOGY, 2017, 37 (02) : 174 - 188
  • [24] Human platelets as a substrate source for the in vitro amplification of the abnormal prion protein (PrPSc) associated with variant Creutzfeldt-Jakob disease
    Jones, Michael
    Peden, Alexander H.
    Yull, Helen
    Wight, Darren
    Bishop, Matthew T.
    Prowse, Chris V.
    Turner, Marc L.
    Ironside, James W.
    MacGregor, Ian R.
    Head, Mark W.
    TRANSFUSION, 2009, 49 (02) : 376 - 384
  • [25] Risk factors for sporadic Creutzfeldt-Jakob disease
    Kittner, C.
    Heinemann, U.
    Zerr, I.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2009, 134 (27) : 1429 - 1434
  • [26] Estimation of variant Creutzfeldt-Jakob disease infectivity titers in human blood
    Gregori, Luisa
    Yang, Hong
    Anderson, Steven
    TRANSFUSION, 2011, 51 (12) : 2596 - 2602
  • [27] Variant Creutzfeldt-Jakob disease: risk of transmission by blood and blood products
    Ironside, JW
    Head, MW
    HAEMOPHILIA, 2004, 10 : 64 - 69
  • [28] Risk of variant Creutzfeldt-Jakob disease and tonsillectomy
    Ole-Bjørn Tysnes
    European Archives of Oto-Rhino-Laryngology, 2003, 260 : 410 - 411
  • [29] Risk of variant Creutzfeldt-Jakob disease and tonsillectomy
    Tysnes, OB
    EUROPEAN ARCHIVES OF OTO-RHINO-LARYNGOLOGY, 2003, 260 (08) : 410 - 411
  • [30] Neuropathology of the new variant of Creutzfeldt-Jakob disease
    Gonzalo-Pascual, I
    Cuadrado-Corrales, N
    REVISTA DE NEUROLOGIA, 2000, 31 (02) : 160 - 161